Compare HRMY & NEOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | NEOG |
|---|---|---|
| Founded | 2017 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2020 | 1995 |
| Metric | HRMY | NEOG |
|---|---|---|
| Price | $38.12 | $11.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $44.11 | $10.67 |
| AVG Volume (30 Days) | 881.8K | ★ 2.2M |
| Earning Date | 05-07-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.97 | ★ 99.20 |
| EPS | ★ 1.84 | N/A |
| Revenue | $868,453,000.00 | ★ $870,400,000.00 |
| Revenue This Year | $19.75 | N/A |
| Revenue Next Year | $12.88 | N/A |
| P/E Ratio | $20.92 | ★ N/A |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $4.90 |
| 52 Week High | $40.87 | $12.85 |
| Indicator | HRMY | NEOG |
|---|---|---|
| Relative Strength Index (RSI) | 56.72 | 62.89 |
| Support Level | $34.87 | $8.68 |
| Resistance Level | $39.24 | $12.85 |
| Average True Range (ATR) | 1.33 | 0.57 |
| MACD | 0.14 | 0.04 |
| Stochastic Oscillator | 66.49 | 67.24 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.